Clinical impact of, and prognostic stratification by, F-18 FDG PET/CT in head and neck mucosal squamous cell carcinoma
Version of Record online: 11 JUN 2007
Copyright © 2007 Wiley Periodicals, Inc.
Head & Neck
Volume 29, Issue 11, pages 986–995, November 2007
How to Cite
A. Connell, C., Corry, J., Milner, A. D., Hogg, A., Hicks, R. J., Rischin, D. and Peters, L. J. (2007), Clinical impact of, and prognostic stratification by, F-18 FDG PET/CT in head and neck mucosal squamous cell carcinoma. Head Neck, 29: 986–995. doi: 10.1002/hed.20629
- Issue online: 10 OCT 2007
- Version of Record online: 11 JUN 2007
- Manuscript Accepted: 22 DEC 2006
- head and neck;
- squamous cell carcinoma
The aim of this study was to determine prospectively the incremental value of positron emission tomography/computed tomography (PET/CT) over conventional assessment (clinical examination and CT/MRI imaging).
All patients undergoing 18F-fluorodeoxyglucose (FDG)-PET/CT for primary head and neck mucosal squamous cell carcinoma between January 2002 and December 2003 (inclusive) were included in this study provided they had undergone contemporaneous conventional assessment of the head and neck region and had 12 months minimum follow-up.
Seventy-six patients underwent 100 PET/CT scans. The majority of patients (74%) were treated with definitive (chemo)radiotherapy. Median follow-up time was 28 months. PET/CT led to a TNM classification alteration in 34% (12/35), a change in radiotherapy planning technique and/or dose in 29% (10/35), and altered treatment response assessment in 43% (13/30). A complete metabolic response was predictive of overall survival (p = .037).
Our results support incorporation of PET/CT into the management paradigm of head and neck mucosal squamous cell carcinoma. © 2007 Wiley Periodicals, Inc. Head Neck 2007